183 related articles for article (PubMed ID: 16203773)
21. COTI-2, A Novel Thiosemicarbazone Derivative, Exhibits Antitumor Activity in HNSCC through p53-dependent and -independent Mechanisms.
Lindemann A; Patel AA; Silver NL; Tang L; Liu Z; Wang L; Tanaka N; Rao X; Takahashi H; Maduka NK; Zhao M; Chen TC; Liu W; Gao M; Wang J; Frank SJ; Hittelman WN; Mills GB; Myers JN; Osman AA
Clin Cancer Res; 2019 Sep; 25(18):5650-5662. PubMed ID: 31308060
[TBL] [Abstract][Full Text] [Related]
22. p53, p63 and p73 expression in squamous cell carcinomas of the head and neck and their response to cisplatin exposure.
Gwosdz C; Balz V; Scheckenbach K; Bier H
Adv Otorhinolaryngol; 2005; 62():58-71. PubMed ID: 15608418
[TBL] [Abstract][Full Text] [Related]
23. PTEN protects p53 from Mdm2 and sensitizes cancer cells to chemotherapy.
Mayo LD; Dixon JE; Durden DL; Tonks NK; Donner DB
J Biol Chem; 2002 Feb; 277(7):5484-9. PubMed ID: 11729185
[TBL] [Abstract][Full Text] [Related]
24. Cisplatin-induced growth arrest of head and neck cancer cells correlates with increased expression of p16 and p53.
Yip HT; Chopra R; Chakrabarti R; Veena MS; Ramamurthy B; Srivatsan ES; Wang MB
Arch Otolaryngol Head Neck Surg; 2006 Mar; 132(3):317-26. PubMed ID: 16549753
[TBL] [Abstract][Full Text] [Related]
25. Decreased nuclear expression and increased cytoplasmic expression of ING5 may be linked to tumorigenesis and progression in human head and neck squamous cell carcinoma.
Li X; Nishida T; Noguchi A; Zheng Y; Takahashi H; Yang X; Masuda S; Takano Y
J Cancer Res Clin Oncol; 2010 Oct; 136(10):1573-83. PubMed ID: 20182888
[TBL] [Abstract][Full Text] [Related]
26. Curcumin suppresses growth of head and neck squamous cell carcinoma.
LoTempio MM; Veena MS; Steele HL; Ramamurthy B; Ramalingam TS; Cohen AN; Chakrabarti R; Srivatsan ES; Wang MB
Clin Cancer Res; 2005 Oct; 11(19 Pt 1):6994-7002. PubMed ID: 16203793
[TBL] [Abstract][Full Text] [Related]
27. Reversal of cisplatin resistance with a BH3 mimetic, (-)-gossypol, in head and neck cancer cells: role of wild-type p53 and Bcl-xL.
Bauer JA; Trask DK; Kumar B; Los G; Castro J; Lee JS; Chen J; Wang S; Bradford CR; Carey TE
Mol Cancer Ther; 2005 Jul; 4(7):1096-104. PubMed ID: 16020667
[TBL] [Abstract][Full Text] [Related]
28. Expression of CXCR4 and its down-regulation by IFN-gamma in head and neck squamous cell carcinoma.
Katayama A; Ogino T; Bandoh N; Nonaka S; Harabuchi Y
Clin Cancer Res; 2005 Apr; 11(8):2937-46. PubMed ID: 15837745
[TBL] [Abstract][Full Text] [Related]
29. p53 gene mutations are associated with decreased sensitivity of human lymphoma cells to DNA damaging agents.
Fan S; el-Deiry WS; Bae I; Freeman J; Jondle D; Bhatia K; Fornace AJ; Magrath I; Kohn KW; O'Connor PM
Cancer Res; 1994 Nov; 54(22):5824-30. PubMed ID: 7954409
[TBL] [Abstract][Full Text] [Related]
30. Exogenous mutant p53 DNA enhanced cisplatin-induced apoptosis in TSGH-8301 human bladder cancer cells.
Chang FL; Ling YF; Lai MD
Anticancer Res; 2000; 20(1A):329-36. PubMed ID: 10769676
[TBL] [Abstract][Full Text] [Related]
31. Dominant negative p63 isoform expression in head and neck squamous cell carcinoma.
Sniezek JC; Matheny KE; Westfall MD; Pietenpol JA
Laryngoscope; 2004 Dec; 114(12):2063-72. PubMed ID: 15564824
[TBL] [Abstract][Full Text] [Related]
32. Akt promotes cisplatin resistance in human ovarian cancer cells through inhibition of p53 phosphorylation and nuclear function.
Fraser M; Bai T; Tsang BK
Int J Cancer; 2008 Feb; 122(3):534-46. PubMed ID: 17918180
[TBL] [Abstract][Full Text] [Related]
33. Protein levels of p21, p27, cyclin E and Bax predict sensitivity to cisplatin and paclitaxel in head and neck squamous cell carcinomas.
Taguchi T; Kato Y; Baba Y; Nishimura G; Tanigaki Y; Horiuchi C; Mochimatsu I; Tsukuda M
Oncol Rep; 2004 Feb; 11(2):421-6. PubMed ID: 14719078
[TBL] [Abstract][Full Text] [Related]
34. Evaluation of the chemosensitivity of head and neck cancer cells based on the diverse function of mutated-p53.
Shinagawa Y; Kawamata H; Omotehara F; Nakashiro K; Hoque MO; Furihata T; Horiuchi H; Imai Y; Fujimori T; Fujibayashi T
Int J Oncol; 2003 Feb; 22(2):383-9. PubMed ID: 12527938
[TBL] [Abstract][Full Text] [Related]
35. Functional characterization of novel mutations affecting survivin (BIRC5)-mediated therapy resistance in head and neck cancer patients.
Knauer SK; Unruhe B; Karczewski S; Hecht R; Fetz V; Bier C; Friedl S; Wollenberg B; Pries R; Habtemichael N; Heinrich UR; Stauber RH
Hum Mutat; 2013 Feb; 34(2):395-404. PubMed ID: 23161837
[TBL] [Abstract][Full Text] [Related]
36. INK4a-ARF alterations and p53 mutations in primary and consecutive squamous cell carcinoma of the head and neck.
Weber A; Bellmann U; Bootz F; Wittekind C; Tannapfel A
Virchows Arch; 2002 Aug; 441(2):133-42. PubMed ID: 12189502
[TBL] [Abstract][Full Text] [Related]
37. Signaling via ErbB2 and ErbB3 associates with resistance and epidermal growth factor receptor (EGFR) amplification with sensitivity to EGFR inhibitor gefitinib in head and neck squamous cell carcinoma cells.
Erjala K; Sundvall M; Junttila TT; Zhang N; Savisalo M; Mali P; Kulmala J; Pulkkinen J; Grenman R; Elenius K
Clin Cancer Res; 2006 Jul; 12(13):4103-11. PubMed ID: 16818711
[TBL] [Abstract][Full Text] [Related]
38. Low-dose fractionated radiation potentiates the effects of Paclitaxel in wild-type and mutant p53 head and neck tumor cell lines.
Dey S; Spring PM; Arnold S; Valentino J; Chendil D; Regine WF; Mohiuddin M; Ahmed MM
Clin Cancer Res; 2003 Apr; 9(4):1557-65. PubMed ID: 12684432
[TBL] [Abstract][Full Text] [Related]
39. Characterization of a head and neck cancer-derived cell line panel confirms the distinct TP53-proficient copy number-silent subclass.
van Harten AM; Poell JB; Buijze M; Brink A; Wells SI; René Leemans C; Wolthuis RMF; Brakenhoff RH
Oral Oncol; 2019 Nov; 98():53-61. PubMed ID: 31541927
[TBL] [Abstract][Full Text] [Related]
40. A novel nuclear factor-kappaB gene signature is differentially expressed in head and neck squamous cell carcinomas in association with TP53 status.
Lee TL; Yang XP; Yan B; Friedman J; Duggal P; Bagain L; Dong G; Yeh NT; Wang J; Zhou J; Elkahloun A; Van Waes C; Chen Z
Clin Cancer Res; 2007 Oct; 13(19):5680-91. PubMed ID: 17908957
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
